Rockefeller Capital Management
BMRN icon

Rockefeller Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rockefeller Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21M Buy
372,197
+10,626
+3% +$620K 0.04% 431
2025
Q4 		$21.5M Buy
361,571
+5,043
+1% +$275K 0.04% 424
2025
Q3 		$19.3M Buy
356,528
+33,045
+10% +$1.89M 0.04% 430
2025
Q2 		$17.8M Buy
323,483
+18,081
+6% +$1.06M 0.04% 423
2025
Q1 		$21.6M Buy
305,402
+2,902
+1% +$195K 0.05% 341
2024
Q4 		$19.9M Buy
302,500
+35,867
+13% +$2.4M 0.05% 343
2024
Q3 		$18.7M Buy
266,633
+37,805
+17% +$3.16M 0.05% 358
2024
Q2 		$18.8M Buy
228,828
+20,172
+10% +$1.68M 0.05% 336
2024
Q1 		$18.2M Buy
208,656
+18,200
+10% +$1.63M 0.05% 354
2023
Q4 		$18.4M Buy
190,456
+10,760
+6% +$952K 0.06% 305
2023
Q3 		$15.9M Sell
179,696
-372,811
-67% -$33.2M 0.06% 317
2023
Q2 		$47.9M Sell
552,507
-176,939
-24% -$16.7M 0.19% 137
2023
Q1 		$70.9M Buy
729,446
+202,410
+38% +$21M 0.31% 78
2022
Q4 		$54.5M Sell
527,036
-492,384
-48% -$46.2M 0.27% 87
2022
Q3 		$86.4M Sell
1,019,420
-98,181
-9% -$8.74M 0.45% 48
2022
Q2 		$92.6M Sell
1,117,601
-14,734
-1% -$1.17M 0.49% 41
2022
Q1 		$87.3M Sell
1,132,335
-7,502
-0.7% -$628K 0.42% 53
2021
Q4 		$101M Sell
1,139,837
-12,022
-1% -$992K 0.47% 40
2021
Q3 		$89M Buy
1,151,859
+338,406
+42% +$26.7M 0.47% 40
2021
Q2 		$67.9M Buy
813,453
+53,161
+7% +$4.21M 0.38% 52
2021
Q1 		$57.4M Sell
760,292
-120,044
-14% -$9.81M 0.39% 53
2020
Q4 		$77.2M Buy
880,336
+4,800
+0.5% +$381K 0.58% 33
2020
Q3 		$66.6M Buy
875,536
+335,439
+62% +$33.9M 0.62% 26
2020
Q2 		$66.6M Buy
540,097
+532,179
+6,721% +$52.9M 0.7% 25
2020
Q1 		$669K Buy
7,918
+3,956
+100% +$341K 0.01% 548
2019
Q4 		$335K Buy
3,962
+74
+2% +$5.59K ﹤0.01% 649
2019
Q3 		$262K Buy
3,888
+3,132
+414% +$241K ﹤0.01% 573
2019
Q2 		$65K Sell
756
-621
-45% -$53.1K ﹤0.01% 773
2019
Q1 		$122K Buy
+1,377
New +$128K ﹤0.01% 709

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's BMRN Position: Q1 2026 in Review

Rockefeller Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 2.9% in Q1 2026, buying an estimated $620K and bringing the position to 372,197 shares worth $21M. The position accounts for 0.04% of the portfolio, ranked #431.

Rockefeller Capital Management first reported a position in BMRN in Q1 2019 and has held it in 29 quarters since. The position peaked at $101M in Q4 2021. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Rockefeller Capital Management held 372,197 shares of BioMarin Pharmaceuticals worth $21M as of Q1 2026.
  • Rockefeller Capital Management bought 10,626 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $620K.
  • BioMarin Pharmaceuticals made up 0.04% of Rockefeller Capital Management's portfolio in Q1 2026, its #431 holding.
  • Rockefeller Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Rockefeller Capital Management's BioMarin Pharmaceuticals position peaked at $101M in Q4 2021.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.